Cargando…

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) and tendonitis and tendon rupture through the Food and Drug Administration Adverse Event Reporting System (FAERS) database....

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Yamin, Zhang, Qilin, He, Xucheng, Liu, Yanxin, Wu, Pan, Chen, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486157/ https://www.ncbi.nlm.nih.gov/pubmed/36147351 http://dx.doi.org/10.3389/fphar.2022.990241

Ejemplares similares

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
por: Zhou, Xiang, et al.
Publicado: (2021)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
por: Wan, Qing, et al.
Publicado: (2022)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
por: Liu, Leping, et al.
Publicado: (2023)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
por: Tang, Shu, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
por: Wu, Bin, et al.
Publicado: (2022)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase
por: Battini, Vera, et al.
Publicado: (2023)

Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS
por: Chai, Shuang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan
por: Chang, Chun-Kai, et al.
Publicado: (2022)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
por: Seo, Heenam, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

Spontaneous bilateral patellar tendon rupture: case report and review of fluoroquinolone‐induced tendinopathy
por: Rosa, Bárbara, et al.
Publicado: (2016)

Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study
por: Morales, Daniel R, et al.
Publicado: (2018)

Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study
por: Morales, Daniel R, et al.
Publicado: (2019)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Achilles Tendon Rupture
por: Stickles, Sean P., et al.
Publicado: (2015)

Quadriceps tendon rupture
por: Nori, Subhadra
Publicado: (2018)

Management of acute Achilles tendon rupture with tendon-bundle technique
por: Li, Chun-Guang, et al.
Publicado: (2017)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Death following bilateral complete Achilles tendon rupture in a patient on fluoroquinolone therapy: a case report
por: Gottschalk, Andrew W, et al.
Publicado: (2009)

Chronic quadriceps tendon rupture: quadriceps tendon reconstruction using ipsilateral semitendinosus tendon graft
por: Oliva, Francesco, et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Bilateral patellar tendon rupture.
por: Hannon, R. J.
Publicado: (1990)

Bilateral patellar tendon rupture
por: Divani, Kiran, et al.
Publicado: (2013)

Chronic Achilles Tendon Rupture
por: Maffulli, Nicola, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sdm35u63gp8hjr5fk7gkvruo8m